[
  {
    "ts": null,
    "headline": "JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra",
    "summary": "J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.",
    "url": "https://finnhub.io/api/news?id=2a43ef0e0cc150979373bf87a86a1357fc6cfc401a2250527bd0b8b0e0e6c617",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757694960,
      "headline": "JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra",
      "id": 136726563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.",
      "url": "https://finnhub.io/api/news?id=2a43ef0e0cc150979373bf87a86a1357fc6cfc401a2250527bd0b8b0e0e6c617"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock",
    "summary": "ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.",
    "url": "https://finnhub.io/api/news?id=a1ec1ae61613d11406cd0066252bff369cc80a2884208951370aaa6a6b53b448",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757686860,
      "headline": "AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock",
      "id": 136726544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.",
      "url": "https://finnhub.io/api/news?id=a1ec1ae61613d11406cd0066252bff369cc80a2884208951370aaa6a6b53b448"
    }
  },
  {
    "ts": null,
    "headline": "Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?",
    "summary": "Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.",
    "url": "https://finnhub.io/api/news?id=3c0abd9f347cd4eea93e8c5222da62ae042bce6e2a949bc0f3e21b06637e4c01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757686080,
      "headline": "Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?",
      "id": 136711252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.",
      "url": "https://finnhub.io/api/news?id=3c0abd9f347cd4eea93e8c5222da62ae042bce6e2a949bc0f3e21b06637e4c01"
    }
  },
  {
    "ts": null,
    "headline": "India's Vadilal Industries U.S. unit to make ice creams locally to cut imports",
    "summary": "(Reuters) -The U.S. subsidiary of India’s Vadilal Industries will start manufacturing ice cream at its local facility by the year-end to reduce dependence on imports and boost sales, an executive of the unit said on Friday.  Vadilal Industries USA currently imports a majority of its products from India.  U.S. President Donald Trump last month imposed tariffs of up to 50% on Indian goods, sending exporters of everything from apparel to frozen shrimp into a frenzy and forcing them to work out contingency plans.",
    "url": "https://finnhub.io/api/news?id=453eaff4ee0f13858154a51162580e5eba9693c6f4dad1baf2024ca8d4ea7a87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757684753,
      "headline": "India's Vadilal Industries U.S. unit to make ice creams locally to cut imports",
      "id": 136711253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "(Reuters) -The U.S. subsidiary of India’s Vadilal Industries will start manufacturing ice cream at its local facility by the year-end to reduce dependence on imports and boost sales, an executive of the unit said on Friday.  Vadilal Industries USA currently imports a majority of its products from India.  U.S. President Donald Trump last month imposed tariffs of up to 50% on Indian goods, sending exporters of everything from apparel to frozen shrimp into a frenzy and forcing them to work out contingency plans.",
      "url": "https://finnhub.io/api/news?id=453eaff4ee0f13858154a51162580e5eba9693c6f4dad1baf2024ca8d4ea7a87"
    }
  },
  {
    "ts": null,
    "headline": "What Looms Ahead After The Dow Jones Topped A Record Of 46,000",
    "summary": "Dow Jones hits record 46,000 amid tech and AI gains. What does this mean for investors for the rest of this year? Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=7368aed8560d1a68ee92c89e62e983ce65e339a65d34a6156618d09607b13226",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757684698,
      "headline": "What Looms Ahead After The Dow Jones Topped A Record Of 46,000",
      "id": 136726369,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1854380206/image_1854380206.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Dow Jones hits record 46,000 amid tech and AI gains. What does this mean for investors for the rest of this year? Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=7368aed8560d1a68ee92c89e62e983ce65e339a65d34a6156618d09607b13226"
    }
  },
  {
    "ts": null,
    "headline": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
    "summary": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
    "url": "https://finnhub.io/api/news?id=3387d29111b12069d5ee62a2ad841c5e7203ebe3f3d48cdf8d0b27d9191a4bd0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757679060,
      "headline": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
      "id": 136751490,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
      "url": "https://finnhub.io/api/news?id=3387d29111b12069d5ee62a2ad841c5e7203ebe3f3d48cdf8d0b27d9191a4bd0"
    }
  },
  {
    "ts": null,
    "headline": "Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors",
    "summary": "MONTPELLIER, France, September 12, 2025--Regulatory News: Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon.",
    "url": "https://finnhub.io/api/news?id=a413c107c9e0cbd222b88348a81a331e01be0cb64ab428641b6f37e154965a6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757658600,
      "headline": "Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors",
      "id": 136711254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MONTPELLIER, France, September 12, 2025--Regulatory News: Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon.",
      "url": "https://finnhub.io/api/news?id=a413c107c9e0cbd222b88348a81a331e01be0cb64ab428641b6f37e154965a6a"
    }
  },
  {
    "ts": null,
    "headline": "Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer",
    "summary": "Johnson & Johnson today announced positive topline results for overall survival (OS) from the Asia cohort of the Phase 3 MARIPOSA study, evaluating amivantamab plus lazertinib as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. In this cohort, where EGFR mutations are more common than in other regions, the chemotherapy-free combination",
    "url": "https://finnhub.io/api/news?id=b59a1a2af6dff219d43c775191d9e7e62068cdf5aa97846c10ae64814e91670c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757649600,
      "headline": "Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer",
      "id": 136711255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson today announced positive topline results for overall survival (OS) from the Asia cohort of the Phase 3 MARIPOSA study, evaluating amivantamab plus lazertinib as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. In this cohort, where EGFR mutations are more common than in other regions, the chemotherapy-free combination",
      "url": "https://finnhub.io/api/news?id=b59a1a2af6dff219d43c775191d9e7e62068cdf5aa97846c10ae64814e91670c"
    }
  }
]